Form 4: EyePoint Pharmaceuticals CEO Transfers Shares to Family Trust
SEC Form 4
Jay S. Duker, President and CEO of EyePoint Pharmaceuticals, transferred 2,500 shares of common stock to a family trust on February 27, 2024.
Summary
- On February 27, 2024, Jay S. Duker, the President and CEO of EyePoint Pharmaceuticals, transferred 2,500 shares of the company's common stock to a family trust.
- Following the transaction, Duker directly owns 29,420 shares and the Family Trust owns 22,500 shares.
- The reporting person's spouse is trustee of the Family Trust.
- Duker disclaims beneficial ownership of the shares held in the family trust.
Sentiment
Score: 5
Explanation: This Form 4 filing is a neutral event, simply reporting a transfer of shares. It doesn't inherently indicate positive or negative sentiment regarding the company's performance.
Industry Context
This is a routine disclosure of insider transactions and doesn't necessarily reflect a change in the company's outlook or performance.
Related Party Transactions
- The transfer of shares to a family trust constitutes a related party transaction.
Stakeholder Impact
- The impact on stakeholders is likely minimal, as this is a personal transaction of an executive and doesn't directly affect the company's operations or financial condition.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of stock transfer to family trust |
| 02/28/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.